Jeil Pharmaceutical Co., Ltd.
↗Seoul, South Korea
Jeil Pharmaceutical is a prominent South Korean pharmaceutical company founded in 1959. It is engaged in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products, including finished drugs and active pharmaceutical ingredients (APIs).
The company operates across multiple therapeutic areas, including oncology, cardiovascular, gastrointestinal, neuropsychiatry, and infectious diseases. It maintains significant R&D capabilities through its Central R&D Center and Pharmaceutical Technology Research Institute, focusing on innovative new drugs, incrementally modified drugs (IMDs), and generics.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty & Generic Pharmaceuticals
SIZE & FINANCIALS
Employees:501-1000
Revenue:$500M-$600M
Founded:1959
Ownership:public
Status:operating
STOCK
Exchange:Korea Stock Exchange (KOSPI)
Ticker:271980
Market Cap:$0.09B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule, ADC, PDC
Active Trials:52
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Jeil Pharma Holdings Inc., Onconic Therapeutics, Inc., Jeil Health Science, Inc.
Key Partnerships:Shionogi & Co., Ltd. (Long-term strategic relationship)
COMPETITION
Position:Niche Player
Competitors:AstraZeneca, HK inno.N, LG Chem Life Sciences
LEADERSHIP
Key Executives:
Seok-Jae Sung - CEO
LINKS
Website:jeilpharm.co.kr
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Jeil Pharmaceutical Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Jeil Pharmaceutical Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.